VF
HCWB icon

Virtu Financial’s HCW Biologics HCWB Stock Holding History

Virtu Financial’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Buy
+7,968
New +$41.2K ﹤0.01% 1410
2025
Q1 		– Sell
-65
Closed -$7K – 1634
2024
Q4 		$7K Buy
+65
New +$7.58K ﹤0.01% 1412

Other funds holding HCWB

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Virtu Financial's HCWB Position: Q1 2026 in Review

Virtu Financial opened a new position in HCW Biologics (HCWB) in Q1 2026: 7,968 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #1410 among its holdings. This is a return to the name: Virtu Financial previously reported a position in HCWB as recently as Q4 2024.

Virtu Financial first reported a position in HCWB in Q4 2024 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • Virtu Financial held 7,968 shares of HCW Biologics worth $17K as of Q1 2026.
  • HCW Biologics was a new Virtu Financial position in Q1 2026.
  • HCW Biologics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1410 holding.
  • Virtu Financial first reported a position in HCW Biologics in Q4 2024 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.